Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients

Purpose: Adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TIL) has shown promising results in metastatic melanoma patients. Although objective response rates of over 50% have been reported, disadvantages of this approach are the labor-intensive TIL production and a very high drop-out rate of enrolled patients, limiting its widespread applicability. Previous studies showed a clear correlation between short TIL culture periods and clinical response. Therefore, we used a new TIL production technique using unselected, minimally cultured, bulk TIL (Young-TIL). The use of Young-TIL is not restricted to human leukocyte antigen (HLA)-A2 patients. The purpose of this study is to explore the efficacy and toxicity of adoptively transferred Young-TIL following lympho-depleting chemotherapy in metastatic melanoma patients, refractory to interleukin-2 and chemotherapy. Experimental Design: Young-TIL cultures for 90% of the patients were successfully generated, enabling the treatment of most enrolled patients. We report here the results of 20 evaluated patients. Results: Fifty percent of the patients achieved an objective clinical response according to the Response Evaluation Criteria in Solid Tumors, including two ongoing complete remissions (20+, 4+ months) and eight partial responses (progression-free survival: 18+, 13+, 10+, 9, 6+, 4, 3+, and 3 months). All responders are currently alive. Four additional patients showed disease stabilization. Side effects were transient and manageable. Conclusion: We showed that lympho-depleting chemotherapy followed by transfer of short-term cultured TIL can mediate tumor regression in 50% of metastatic melanoma with manageable toxicity. The convincing clinical results combined with the simplification of the process may thus have a major effect on cell therapy of cancer. Clin Cancer Res; 16(9); 2646–55. ©2010 AACR.

• Publication year

  2010

• Venue

  Clinical Cancer Research

• Publication date

  2010-04-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-10-0041PMID 20406835
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adoptive cell therapy for the treatment of patients with metastatic melanoma.

  2009cited by this paper
• Minimally Cultured or Selected Autologous Tumor-infiltrating Lymphocytes After a Lympho-depleting Chemotherapy Regimen in Metastatic Melanoma Patients

  2009influential reference
• Collection of Large-scale Expanded Lymphocyte Cultures for Adoptive Immunotherapy Using a COBE Spectra Apheresis Machine

  2008cited by this paper
• Adoptive cell transfer: a clinical path to effective cancer immunotherapy

  2008cited by this paper
• Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

  2008influential reference
• Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy

  2008cited by this paper
• Persistence of Tumor Infiltrating Lymphocytes in Adoptive Immunotherapy Correlates With Telomere Length

  2007cited by this paper
• Adoptive cell transfer therapy.

  2007cited by this paper
• Cutaneous melanoma: available therapy for metastatic disease

  2006cited by this paper
• Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy1

  2005cited by this paper
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

  2005influential reference
• Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy.

  2005cited by this paper
• Management of cutaneous melanoma.

  2004cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients

  2003influential reference
• High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.

  1994cited by this paper
• Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.

  1992cited by this paper
• Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response.

  1991cited by this paper
• Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred

  year unknowncited by this paper

• Tumour-infiltrating lymphocyte therapy in melanoma: ready for prime time?

  2026cites this paper
• Value of information analyses for advanced cell therapies: a systematic review.

  2026cites this paper
• Non-Genetically Modified Adoptive Cell Therapies for Solid Tumors: Current Landscape and Future Challenges

  2026cites this paper
• Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment

  2025cites this paper
• Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα

  2025cites this paper
• Engineering adoptive cell therapy for solid tumors

  2025cites this paper
• Mechanisms of resistance to adoptive cell therapy with tumor-infiltrating lymphocytes

  2025cites this paper
• Autologous T-Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities.

  2025cites this paper
• The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma.

  2025cites this paper
• Application of adoptive cell therapy in malignant melanoma

  2025cites this paper
• γδ T cells are the prime antitumoral T cells in pediatric neuroblastoma

  2025cites this paper
• Differential effects of immobilized CCL21 and ICAM1 on TILs with distinct expansion properties

  2025cites this paper
• Adoptive T-Cell Therapy in Melanoma: How This Will Impact Surgical Practice and the Role of Surgeons.

  2025cites this paper
• Advances in TIL therapy: Expanding the horizons beyond melanoma.

  2025cites this paper
• The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers.

  2025cites this paper
• Tumor infiltration therapy: from FDA approval to next-generation approaches

  2025cites this paper
• Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges

  2025cites this paper
• Tumour-infiltrating lymphocytes in refractory melanoma - not as hard as we thought?

  2025cites this paper
• Leveraging Immunological Properties of Nucleic Acid Nanoparticles to Improve Cancer Therapy

  2025cites this paper
• Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial

  2024cites this paper
• Biomarkers for response to TIL therapy: a comprehensive review

  2024cites this paper
• Entering a new era of tumor-infiltrating lymphocyte cell therapy innovation.

  2024cites this paper
• Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system

  2024cites this paper
• Solid tumour cellular therapy — principles of toxicity management

  2024cites this paper
• Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells

  2024cites this paper
• Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors

  2024cites this paper
• Adoptive T cell therapy for solid tumors: current landscape and future challenges

  2024cites this paper
• Technological search of patents for the identification of devices with potential use in Tumor-infiltrating lymphocytes (TILs) research

  2024cites this paper
• Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products

  2024cites this paper
• Immunotherapy for colorectal cancer

  2024cites this paper
• Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness

  2024cites this paper
• Non-viral delivery of RNA for therapeutic T cell engineering.

  2024cites this paper
• TIL Therapy in Lung Cancer: Current Progress and Perspectives

  2024cites this paper
• Modelagem Matemática da Imunoterapia para Tumores: Análise Computacional da Terapia Celular Adotiva com Interleucina-2

  2024cites this paper
• Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma

  2023cites this paper
• CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours

  2023cites this paper
• Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1+CD8+ T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer

  2023cites this paper
• TIL Therapy: Facts and Hopes.

  2023cites this paper
• MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2.

  2023cites this paper
• Advances in adoptive T-cell therapy for metastatic melanoma.

  2023cites this paper
• IL-7R licenses a population of epigenetically poised memory CD8+ T cells with superior antitumor efficacy that are critical for melanoma memory

  2023cites this paper
• Modulating the proliferative and cytotoxic properties of patient-derived TIL by a synthetic immune niche of immobilized CCL21 and ICAM1

  2023cites this paper
• Tissue-resident memory T cells in gastrointestinal tumors: turning immune desert into immune oasis

  2023cites this paper
• Immunotherapy in Melanoma: Recent Advances and Future Directions

  2023cites this paper
• “One more chance to survive”: the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy—a qualitative study and recommendations for future care

  2023cites this paper
• Advances in the development of tumor-infiltrating lymphocyte therapy for advanced melanoma

  2023cites this paper
• Novel cellular therapies for hepatobiliary malignancies.

  2022cites this paper
• Novel IKZF3 transcriptomic signature correlates with positive outcomes of skin cutaneous melanoma: A pan-cancer analysis

  2022cites this paper
• Immune-based therapies in penile cancer

  2022cites this paper
• Immunotherapy Options for Acral Melanoma, A fast-growing but Neglected Malignancy.

  2022cites this paper
• Adenosine-deaminase-acting-on-RNA-1 facilitates T-cell migration toward human melanoma cells.

  2022cites this paper
• The Next Generation of Cellular Immunotherapy: CAR-NK Cells.

  2022cites this paper
• Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future

  2022cites this paper
• Modulating the proliferative and cytotoxic properties of human TIL by a synthetic immune niche of immobilized CCL21 and ICAM1

  2022cites this paper
• Adoptive T-cell Immunotherapy: Perfecting Self-Defenses.

  2022cites this paper
• Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen

  2022cites this paper
• Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes

  2022cites this paper
• Safety evaluation of the mouse TCRα - transduced T cell product in preclinical models in vivo and in vitro.

  2022cites this paper
• A Toolkit for Profiling the Immune Landscape of Pediatric Central Nervous System Malignancies

  2022cites this paper
• Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer

  2022cites this paper
• Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges

  2022cites this paper
• Membrane anchored IL-18 linked to constitutively active TLR4 and CD40 improves human T cell antitumor capacities for adoptive cell therapy

  2022cites this paper
• Integrated analysis reveals the pivotal interactions between immune cells in the melanoma tumor microenvironment

  2022cites this paper
• The evolving landscape of immunotherapy in solid tumors

  2021cites this paper
• CD137+ T-Cells: Protagonists of the Immunotherapy Revolution

  2021cites this paper
• Genetic Modification of Tumor-Infiltrating Lymphocytes via Retroviral Transduction

  2021cites this paper
• Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ Specificity and Treatment Resistance

  2021cites this paper
• The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications

  2021cites this paper
• Bone marrow toxicity and immune reconstitution in melanoma and non-melanoma solid cancer patients after non-myeloablative conditioning with chemotherapy and checkpoint inhibition.

  2021cites this paper
• Vaccine-Enhanced Adoptive T-Cell Therapy to Treat Canine Cancers

  2021cites this paper
• Notch Signaling in Embryology and Cancer: Notch Signaling in Cancer

  2021cites this paper
• ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors

  2021cites this paper
• Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies

  2021cites this paper
• The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer

  2021cites this paper
• The therapeutic potential of multiclonal tumoricidal T cells derived from tumor infiltrating lymphocyte-derived iPS cells

  2021cites this paper
• Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

  2021cites this paper
• Immunoscore Signatures in Surgical Specimens and Tumor-Infiltrating Lymphocytes in Pretreatment Biopsy Predict Treatment Efficacy and Survival in Esophageal Cancer

  2021cites this paper
• Adoptive NK Cell Therapy: A Promising Treatment Prospect for Metastatic Melanoma

  2021cites this paper
• The therapeutic potential of multiclonal tumoricidal T cells derived from tumor infiltrating lymphocyte-derived iPS cells

  2021cites this paper
• Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ

  2021cites this paper
• A New Tumor-Immunotherapy Regimen based on Impulsive Control Strategy

  2020cites this paper
• Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy

  2020cites this paper
• A systematic review of economic evaluations of advanced therapy medicinal products

  2020cites this paper
• Cell Reprogramming for Immunotherapy: Methods and Protocols

  2020cites this paper
• A functional pre-screening platform for identifying points of vulnerability in the cell death map of human melanoma tumors

  2020cites this paper
• Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial

  2020cites this paper
• Key Factors in Clinical Protocols for Adoptive Cell Therapy in Melanoma.

  2020cites this paper
• Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients

  2020cites this paper
• microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapy

  2020cites this paper
• Overcoming Immune Evasion in Melanoma

  2020cites this paper
• Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up

  2020cites this paper
• Adoptive T Cell Therapy with IL-12–Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity

  2020cites this paper
• The Landscape of Tumor-Specific Antigens in Colorectal Cancer

  2020cites this paper
• Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy

  2020cites this paper
• Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade

  2020cites this paper
• IL6 Fuels Durable Memory for Th17 Cell–Mediated Responses to Tumors

  2020cites this paper
• Adoptive cell transfer (ACT) of autologous tumor‐infiltrating lymphocytes (TILs) to treat malignant melanoma: the dawn of a chimeric antigen receptor T (CAR‐T) cell therapy from autologous donor

  2020cites this paper
• Lymph nodes may be a source for immunetherapy in gastric cancer

  2020cites this paper
• Prognostic significance of tumor-infiltrating lymphocytes (TILs) and their characterization in canine melanocytic tumors.

  2020cites this paper
• In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes

  2020cites this paper